Management of a New Isolated Metastasis during Sunitinib Treatment in Renal Cell Carcinoma Patients: A Lesson from Two Cases

被引：5

作者：

Shablak, Alaaeldin ^{[1
]}

O'Dwyer, Jackie ^{[1
]}

Hawkins, Robert ^{[1
]}

Board, Ruth ^{[1
]}

机构：

[1] Christie NHS Fdn Trust, Dept Med Oncol, Manchester M20 4BX, Lancs, England

来源：

UROLOGIA INTERNATIONALIS | 2011年 / 86卷 / 02期

关键词：

Renal cell carcinoma; Sunitinib; Radiotherapy; ANTIANGIOGENIC THERAPY; TARGETED THERAPY; CANCER; SURVIVAL; EFFICACY; INTERLEUKIN-2; CHEMOTHERAPY; STRATEGIES; GUIDELINES; RESISTANCE;

D O I：

10.1159/000321908

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Metastatic renal cell carcinoma (mRCC) is a difficult to treat malignancy and currently Sunitinib is a standard of care first-line therapy. A new metastasis during the treatment is considered a sign of drug failure and alternative therapeutic methods should be tried. Here, we report 2 cases of newly diagnosed isolated metastasis during Sunitinib treatment of mRCC patients. Our management plan included local palliative therapy to the lesion followed by recommencing of Sunitinib. This resulted in a good symptomatic relief locally as well as good overall control of the disease. Copyright (c) 2010 S. Karger AG, Basel

引用

页码：245 / 248

页数：4

共 30 条

[1] Immunotherapeutic strategies in kidney cancer - when TKIs are not enough [J].

Biswas, Swethajit ;

Eisen, Tim .

NATURE REVIEWS CLINICAL ONCOLOGY, 2009, 6 (08) :478-487

[2] Retrospective Analysis of the Safety and Efficacy of Interleukin-2 After Prior VEGF-targeted Therapy in Patients With Advanced Renal Cell Carcinoma [J].

Cho, Daniel C. ;

Puzanov, Igor ;

Regan, Meredith M. ;

Schwarzberg, Talya ;

Seery, Virginia ;

Lee, Mee-Young ;

Liu, Vivian ;

Bhatt, Rupal ;

Koon, Henry ;

Mier, James W. ;

Sosman, Jeffrey A. ;

Atkins, Michael B. ;

McDermott, David F. .

JOURNAL OF IMMUNOTHERAPY, 2009, 32 (02) :181-185

[3] Renal-cell carcinoma [J].

Cohen, HT ;

McGovern, FJ .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (23) :2477-2490

[4] Anti-vascular tumor therapy: recent advances, pitfalls and clinical perspectives [J].

Eichhorn, ME ;

Strieth, S ;

Dellian, M .

DRUG RESISTANCE UPDATES, 2004, 7 (02) :125-138

[5] Advanced renal cell carcinoma - current and emerging management strategies [J].

Escudier, Bernard .

DRUGS, 2007, 67 (09) :1257-1264

[6] Long-term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy [J].

Fyfe, GA ;

Fisher, RI ;

Rosenberg, SA ;

Sznol, M ;

Parkinson, DR ;

Louie, AC .

JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (08) :2410-2411

[7]

HARRIS DT, 1983, SEMIN ONCOL, V10, P422

[8] Bevacizurnab in combination with fluorouracil and leucovorin: An active regimen for first-line metastatic colorectal cancer [J].

Hurwitz, HI ;

Fehrenbacher, L ;

Hainsworth, JD ;

Heim, W ;

Berlin, J ;

Holmgren, E ;

Hambleton, J ;

Novotny, WF ;

Kabbinavar, F .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (15) :3502-3508

[9] Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy [J].

Jain, RK .

SCIENCE, 2005, 307 (5706) :58-62

[10] Antiangiogenic therapy: A universal chemosensitization strategy for cancer? [J].

Kerbel, Robert S. .

SCIENCE, 2006, 312 (5777) :1171-1175

← 1 2 3 →